Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13904060 | 1.00 | APLNR (0.33) | APLNR | |
| SCHEMBL15580613 | 0.92 | APLNR (0.32) | APLNR | |
| SCHEMBL13904061 | 0.92 | APLNR (0.32) | APLNR | |
| SCHEMBL12772109 | 0.92 | APLNR (0.32) | APLNR | |
| SCHEMBL17082369 | 0.91 | APLNR (0.33) | APLNR | |
| SCHEMBL13904056 | 0.89 | APLNR (0.31) | APLNR | |
| SCHEMBL12772099 | 0.88 | APLNR (0.32) | APLNR | |
| SCHEMBL13904057 | 0.87 | APLNR (0.31) | APLNR | |
| SCHEMBL12769332 | 0.85 | APLNR (0.31) | APLNR | |
| SCHEMBL13155308 | 0.85 | APLNR (0.31) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308861-B1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI R&D MAN CO LTD (JP) | 2017-03-01 | — | — | EP | disclosed |
| EP-1507773-B1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI R&D MAN CO LTD (JP) | 2015-09-16 | — | — | EP | disclosed |
| US-7915306-B2 | For therapy of inflammatory or autoimmune disorders | EISAI CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7799827-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20090082313-A1 | Multikinase Inhibitors for Use in the Treatment of Cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082313-A1 | Multikinase Inhibitors for Use in the Treatment of Cancer | EGFR, ERBB3, FLT3 | APLNR 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.